On the basis of serum ALB–BIL grade, the pre-treatment serum PLT–ALB–BIL grade has been developed as another serum ALB-based biomarker and has been validated with prognostic value in HCC patients in multiple lines of studies (Table 6). Here, ALB is linked to hepatocellular carcinoma.